ANKTIVA plus BCG meets primary endpoint in randomized BCG-naive NMIBC trial

RCT · Business Wire · 2026-11-09. Number 3 in the UrologyWatch Top 5 for November 16, 2026.

The randomized QUILT-2.005 trial of ANKTIVA (nogapendekin alfa inbakicept) added to BCG met its primary endpoint in patients with BCG-naive non-muscle invasive bladder cancer, according to a company announcement; detailed results were not reported.

Why it matters: A positive randomized readout in the BCG-naive setting could expand use of this combination beyond the BCG-unresponsive population already approved.

Limitation: Topline company announcement; detailed efficacy and safety data not yet available.

Source: Business Wire

The full November 16, 2026 edition · Today's urology news

Loading today's edition…